Loading…
Bionano Genomics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.9% over 5Y.
today you would have $0.50▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.53 | $17.40 | $113.40 | $876.00 | $1,794.00 | $1,848.00 | $744.00 | $3,144.00 | |
| P/S | 4.5x | 0.6x | 1.7x | 2.9x | 16.1x | 48.2x | 100.9x | 4.6x | 4.4x |
| P/B | 2.2x | 0.4x | 1.5x | 1.1x | 1.8x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LGVNLongeveron Inc. | $6.72 | — | 20.5x | — | -203.61% | $21.42M |
| COCPCocrystal Pharma, Inc. | $1.10 | — | 14.5x | — | -311.68% | $21.19M |
| LFWDLifeward Ltd. | $7.46 | — | 3.3x | — | -225.65% | $21.13M |
| CTSOCytosorbents Corp | $0.34 |
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Company description provided by Yahoo Finance.
| 2.6x |
| 24.5x |
| 13.0x |
| 5.2x |
| EPS | -$4.85 | -$88.13 | -$408.60 | -$274.80 | -$156.00 | -$234.00 | -$1,194.00 | -$1,566.00 |
| Profit margin | -383.41% | -92.59% | -363.98% | -643.74% | -476.93% | -402.84% | -483.43% | -294.34% | -154.13% |
| ROE | -149.81% | -59.42% | -316.66% | -241.78% | -53.17% | -21.49% | -117.17% | -825.22% | -182.46% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -336.21% |
| $21.09M |
| RVPRetractable Technologies Inc | $0.73 | — | 0.3x | — | -4.51% | $21.85M |
| AKTXAkari Therapeutics Plc | $10.70 | — | 1.0x | — | -140.09% | $20.83M |